Real-World Use of ICI in Advanced or Recurrent Endometrial Cancer

featured-image

Panelists discuss how real-world studies on immune checkpoint inhibitors (ICIs) in advanced or recurrent endometrial cancer (EC) provide valuable insights into treatment effectiveness, patient outcomes, and the management of adverse events, helping refine treatment strategies, especially for biomarker-driven therapy.

Summary for Physicians: Interpretation of Real-World Use of ICIs in Advanced or Recurrent EC Dr Birrer’s question to Dr Chan regarding the real-world use of ICIs in advanced or recurrent EC pertains to how findings from real-world studies impact clinical practice and treatment strategies. In summary, Dr Chan’s interpretation of the real-world use of ICIs in advanced or recurrent EC would likely focus on how this data supports and refines treatment strategies, especially for biomarker-driven therapy , and how real-world insights help manage treatment sequencing , patient outcomes , and adverse events more effectively in everyday clinical practice..